Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis

By Saloustros Emmanouil   Mavroudis Dimitris  

Future Oncology, Vol. 6, Iss. 2, 2010-02 ,pp. : 209-219

Future Medicine

Access to resources Recommend Favorite

Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with ¹⁸F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’”

By Koolen Bas   Wesseling Jelle  

Annals of Surgical Oncology, Vol. 21, Iss. 2, 2014-02 ,pp. : 700-700

Springer Publishing Company

Access to resources Recommend Favorite

Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on “Early Assessment of Axillary Response with ¹⁸F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)”

By Chao Wan-Ru   Han Chih-Ping  

Annals of Surgical Oncology, Vol. 21, Iss. 2, 2014-02 ,pp. : 699-699

Springer Publishing Company

Access to resources Recommend Favorite

Characteristics of basal cytokeratin expression in breast cancer

By Alshareeda Alaa  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 23-37

Springer Publishing Company

Access to resources Recommend Favorite

Circulating tumour cells in breast cancer

By Ring A.   Smith I.E.   Dowsett M.  

Lancet Oncology, Vol. 5, Iss. 2, 2004-02 ,pp. : 79-88

Elsevier

Access to resources Recommend Favorite